Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Essential Therapeutics discontinues development of ETRX-101

Jan. 8, 2003

Final pivotal phase III trials of AC-2993 complete enrollment

Jan. 8, 2003

Additional thielavins identified as glucose-6-phosphatase inhibitors at Pfizer

Jan. 8, 2003

Metformin XT NDA submitted for type 2 diabetes

Jan. 8, 2003

Genome Therapeutics and Wyeth extend osteoporosis research alliance

Jan. 8, 2003

Nonredox antiobesity cobalt porphyrin complexes discovered at MitoKor

Jan. 7, 2003

Novel prodrugs of FBPase inhibitors prepared and tested at Metabasis Therapeutics

Jan. 3, 2003

New modulators of glucose and lipid levels designed by Dr. Reddy's researchers

Jan. 3, 2003

Highly potent, orally available human glucagon receptor antagonist with antihyperglycemic activity

Jan. 3, 2003

Beneficial long-term effects of arzoxifene on bone and lipids in ovariectomized rats

Jan. 3, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...